BR112013012652A2 - forma de dosagem sólida de oleil fosfocolina para administração oral, forma de dosagem sólida, e método para a preparação de uma forma de dosagem sólida - Google Patents

forma de dosagem sólida de oleil fosfocolina para administração oral, forma de dosagem sólida, e método para a preparação de uma forma de dosagem sólida

Info

Publication number
BR112013012652A2
BR112013012652A2 BR112013012652A BR112013012652A BR112013012652A2 BR 112013012652 A2 BR112013012652 A2 BR 112013012652A2 BR 112013012652 A BR112013012652 A BR 112013012652A BR 112013012652 A BR112013012652 A BR 112013012652A BR 112013012652 A2 BR112013012652 A2 BR 112013012652A2
Authority
BR
Brazil
Prior art keywords
dosage form
solid dosage
phosphocholin
oleyl
preparing
Prior art date
Application number
BR112013012652A
Other languages
English (en)
Inventor
Frans Herwig Jansen
Original Assignee
Dafra Pharma Res & Dev Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dafra Pharma Res & Dev Bvba filed Critical Dafra Pharma Res & Dev Bvba
Publication of BR112013012652A2 publication Critical patent/BR112013012652A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
BR112013012652A 2010-11-22 2011-11-21 forma de dosagem sólida de oleil fosfocolina para administração oral, forma de dosagem sólida, e método para a preparação de uma forma de dosagem sólida BR112013012652A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2010067926 2010-11-22
PCT/EP2011/070592 WO2012069427A1 (en) 2010-11-22 2011-11-21 Solid dosage forms of oleyl phosphocholine

Publications (1)

Publication Number Publication Date
BR112013012652A2 true BR112013012652A2 (pt) 2016-09-06

Family

ID=45047759

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013012652A BR112013012652A2 (pt) 2010-11-22 2011-11-21 forma de dosagem sólida de oleil fosfocolina para administração oral, forma de dosagem sólida, e método para a preparação de uma forma de dosagem sólida

Country Status (7)

Country Link
US (1) US9358244B2 (pt)
BR (1) BR112013012652A2 (pt)
CA (1) CA2818194A1 (pt)
ES (1) ES2634094T3 (pt)
MX (1) MX2013005687A (pt)
PT (1) PT2642981T (pt)
WO (1) WO2012069427A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3136525A1 (en) * 2019-04-12 2020-10-15 Oblita Therapeutics Bvba Tablet dosage formulations of oleyl phosphocholine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
DE4132344A1 (de) 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
SK284839B6 (sk) 1998-01-22 2005-12-01 Zentaris Gmbh Použitie miltefozínu na výrobu lieku a farmaceutická kombinácia na liečenie leishmanózy
BRPI0516937A (pt) * 2004-10-19 2008-09-23 Max Planck Gesellschaft formulações com alquilfosfocolinas na utilização de partìculas portadoras de carga negativa
DE102007014375A1 (de) * 2007-03-26 2008-10-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Oleylphosphocholin

Also Published As

Publication number Publication date
US9358244B2 (en) 2016-06-07
MX2013005687A (es) 2013-10-17
ES2634094T3 (es) 2017-09-26
CA2818194A1 (en) 2012-05-31
PT2642981T (pt) 2017-06-16
WO2012069427A1 (en) 2012-05-31
US20140193493A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
BRPI1011764A2 (pt) composição farmacêutica, e, método para preparar uma composição farmacêutica
BRPI0914918A2 (pt) forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida.
IL228709A0 (en) Dosage unit form for oral administration
BR112014015042A2 (pt) composição farmacêutica, e, método para obter uma composição radiofarmacêutica
IL227383A0 (en) Extended-release oral dosage forms containing tsucitinib
IL222919A0 (en) Alcohol - resistant oral pharmaceutical form
BR112014007645A2 (pt) composto heterocíclico, métodos para a preparação de um composto heterocíclico, e, composição farmacêutica
GB201009237D0 (en) New administration method
BR112013013571A2 (pt) comprimido para a desintegração oral
CO6950486A2 (es) Solución para administración oral
BRPI0922173A2 (pt) preparação farmacêutica, e, método para preparar uma preparação farmacêutica
BRPI1007484A2 (pt) composição farmacêutica para administração oral
BR112013015085A2 (pt) composição farmacêutica, método para preparar uma composição, e, uso de composição
HK1206292A1 (en) Medicament administration
BR112012031102A2 (pt) forma de dosagem oral sólida
HUE038543T2 (hu) MGBG-t tartalmazó szabályozott kibocsátású orális gyógyszerészeti dózis-formák
BRPI0918539A2 (pt) preparação farmacêutica sólida para administração oral
EP2781512A4 (en) OXADIAZOLE COMPOUND AND PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP2668852A4 (en) COMPOSITION FOR ORAL ADMINISTRATION
BRPI0919194A2 (pt) preparação sólida para administração oral
BR112013013415A2 (pt) composição farmacêutica, e, método para a preparação de uma composição
IT1399867B1 (it) Inserto illustrativo per medicinali.
BR112013012652A2 (pt) forma de dosagem sólida de oleil fosfocolina para administração oral, forma de dosagem sólida, e método para a preparação de uma forma de dosagem sólida
HUE040419T2 (hu) Analgetikus gyógyászati kompozíció orális beadásra
BR112013014963A2 (pt) comprimido farmacêutico de liberação controlada para administração oral

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: DAFRA PHARMA N.V. (BE)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements